tmx2a Antibody

What is TMX2 and why is it significant in research?

TMX2 is one of the least studied members of the thioredoxin family of disulfide isomerases. Research has shown that TMX2 is overexpressed in breast cancer samples, including patient-derived tissues and commercial cell lines, suggesting its potential as a novel target for cancer diagnostics and treatment . As a disulfide isomerase, TMX2 likely plays a role in protein folding and cellular redox regulation, though its specific biological functions remain under investigation.

What types of TMX2 antibodies are available for research applications?

Current research tools include:

• Polyclonal antibodies targeting various epitopes (e.g., AA 110-159, N-terminal regions, middle regions)

• Fully human antibodies targeting specific extracellular or intracellular epitopes

• Antibodies with different conjugations for diverse applications (unconjugated, FITC, HRP, Biotin)

• Antibodies validated for multiple techniques including Western Blot, ELISA, IHC, and IF

What is the cross-species reactivity profile of TMX2 antibodies?

The high conservation of TMX2 across species enables broad reactivity of many antibodies, as demonstrated by sequence homology analysis:

BLAST analysis confirms high sequence homology across mammalian species, making many TMX2 antibodies suitable for comparative studies .

What are the recommended applications for TMX2 antibodies?

Based on current validation data, TMX2 antibodies are most commonly used for:

• Western Blotting (WB): Typically at 1 μg/mL in 5% skim milk/PBS buffer with HRP-conjugated secondary antibodies

• Enzyme-Linked Immunosorbent Assay (ELISA): Particularly useful for quantification with detection limits in the nanomolar range

• Immunohistochemistry (IHC): For tissue localization studies

• Immunofluorescence (IF): For subcellular localization studies

• Flow cytometry: For detecting cell surface and intracellular TMX2 expression

How should researchers validate TMX2 antibody specificity for their experimental systems?

A comprehensive validation strategy should include:

• Western blot analysis comparing bands in control versus TMX2 knockdown systems

• Peptide competition assays using the immunizing peptide to confirm specificity

• Surface Plasmon Resonance (SPR) to quantitatively assess antibody-antigen kinetics

• Validation across multiple cell lines with known TMX2 expression profiles

• Cross-validation with multiple antibodies targeting different epitopes

Surface Plasmon Resonance (SPR) has been successfully employed to determine binding kinetics of anti-TMX2 antibodies, with steady-state affinity (KD) measurements around 34 nM using a bivalent interaction model .

What is known about TMX2 subcellular localization and how does this impact antibody selection?

TMX2 has been detected in both the cytoplasm and cell membrane of breast cancer cells through flow cytometry analysis . This dual localization has important implications for antibody selection:

• For live-cell experiments: Antibodies targeting extracellular epitopes are essential

• For fixed-cell applications: Antibodies targeting intracellular domains may provide better specificity

• For functional studies: The epitope location significantly affects biological outcomes

Researchers should select antibodies based on the specific cellular compartment they wish to target, as this impacts both detection sensitivity and biological effects.

How do different anti-TMX2 antibodies affect cellular functions in experimental models?

Studies reveal striking differences in the biological effects of antibodies based on their epitope recognition:

These differential effects highlight the importance of epitope selection when developing therapeutic antibodies. The RGCC intra-TMX2 antibody specifically decreased proliferation of breast cancer cells and altered the expression of genes related to cancer pathways .

What methodology is recommended for purifying TMX2-specific antibodies?

A two-step affinity chromatography approach has proven effective:

The procedure involves first passing the antibody-containing solution through a TMX2 affinity column, followed by an IgG-specific column (e.g., using Protein A/G). Fragment 5, containing IgG antibodies specifically against TMX2, demonstrated the highest specificity and biological activity in functional assays .

What methods are recommended for measuring TMX2 antibody binding kinetics?

Surface Plasmon Resonance (SPR) is the gold standard for determining antibody-antigen interaction parameters:

• Immobilize anti-human IgG antibody on a sensor surface using amino coupling chemistry

• Introduce the TMX2 antibody-containing sample

• Run serial dilutions of purified TMX2 protein (10 nM to 10 μM) over the antibody surface

• Apply a bivalent interaction model for data analysis

• Determine key parameters including KD, association rate (kon), and dissociation rate (koff)

• Verify regeneration capability using glycine elution

This approach has successfully characterized anti-TMX2 antibodies with nanomolar affinity .

How can researchers optimize Western blot detection of TMX2?

For optimal Western blot results with TMX2 antibodies:

• Use 15% polyacrylamide gels to resolve TMX2 protein effectively

• Dilute primary antibodies to approximately 1 μg/mL in 5% skim milk/PBS buffer

• Dilute HRP-conjugated secondary antibodies at 1:50,000–1:100,000

• Include positive controls such as recombinant TMX2 protein

• For cell/tissue lysates, ensure sufficient protein concentration (typically 20-50 μg total protein)

• Incubate primary antibodies overnight at 4°C for optimal sensitivity

What controls should be included when studying the biological effects of TMX2 antibodies?

To ensure experimental rigor when evaluating TMX2 antibody effects:

• Include isotype-matched control antibodies to control for non-specific effects

• Compare commercial antibodies targeting the same epitope regions

• Perform dose-response studies to determine optimal concentration (e.g., 0.05% antibody concentration was found optimal for intracellular TMX2 antibody)

• Include positive controls for the cellular processes being measured

• Verify TMX2 expression in the experimental system before treatment

What is known about the potential of TMX2 as a therapeutic target in cancer?

Research suggests TMX2 may be a promising target for cancer treatment:

• TMX2 is overexpressed in breast cancer samples compared to normal tissue

• Antibodies targeting intracellular epitopes of TMX2 can decrease cancer cell proliferation

• These antibodies also affect the expression of genes related to cancer survival, differentiation, and metastasis

• The differential effects of antibodies targeting different epitopes suggest complex regulatory roles for TMX2

These findings indicate TMX2 may have potential as a therapeutic target, though further research is needed to fully characterize its role in cancer biology and optimize targeting strategies.